| Molecular complexity and its impact on the probability of finding leads for drug discovery MM Hann, AR Leach, G Harper Journal of chemical information and computer sciences 41 (3), 856-864, 2001 | 1173 | 2001 |
| Type IIA topoisomerase inhibition by a new class of antibacterial agents BD Bax, PF Chan, DS Eggleston, A Fosberry, DR Gentry, F Gorrec, ... Nature 466 (7309), 935-940, 2010 | 861 | 2010 |
| Recap retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry XQ Lewell, DB Judd, SP Watson, MM Hann Journal of chemical information and computer sciences 38 (3), 511-522, 1998 | 815 | 1998 |
| Pursuing the leadlikeness concept in pharmaceutical research MM Hann, TI Oprea Current opinion in chemical biology 8 (3), 255-263, 2004 | 676 | 2004 |
| Finding the sweet spot: the role of nature and nurture in medicinal chemistry MM Hann, GM Keserü Nature reviews Drug discovery 11 (5), 355-365, 2012 | 459 | 2012 |
| Molecular obesity, potency and other addictions in drug discovery MM Hann MedChemComm 2 (5), 349-355, 2011 | 417 | 2011 |
| Strategic pooling of compounds for high-throughput screening M Hann, B Hudson, X Lewell, R Lifely, L Miller, N Ramsden Journal of chemical information and computer sciences 39 (5), 897-902, 1999 | 277 | 1999 |
| Modulators of 14-3-3 protein–protein interactions LM Stevers, E Sijbesma, M Botta, C MacKintosh, T Obsil, I Landrieu, ... Journal of medicinal chemistry 61 (9), 3755-3778, 2017 | 257 | 2017 |
| Design principles for fragment libraries: maximizing the value of learnings from pharma fragment-based drug discovery (FBDD) programs for use in academia GM Keserű, DA Erlanson, GG Ferenczy, MM Hann, CW Murray, ... Journal of medicinal chemistry 59 (18), 8189-8206, 2016 | 245 | 2016 |
| Molecular complexity and fragment-based drug discovery: ten years on AR Leach, MM Hann Current opinion in chemical biology 15 (4), 489-496, 2011 | 215 | 2011 |
| Fragment screening: an introduction AR Leach, MM Hann, JN Burrows, EJ Griffen Molecular BioSystems 2 (9), 429-446, 2006 | 214 | 2006 |
| On the double bond isostere of the peptide bond: preparation of an enkephalin analogue MM Hann, PG Sammes, PD Kennewell, JB Taylor Journal of the Chemical Society, Perkin Transactions 1, 307-314, 1982 | 191 | 1982 |
| The in silico world of virtual libraries AR Leach, MM Hann Drug discovery today 5 (8), 326-336, 2000 | 170 | 2000 |
| Stabilization of protein-protein interactions in drug discovery SA Andrei, E Sijbesma, M Hann, J Davis, G O’Mahony, MWD Perry, ... Expert opinion on drug discovery 12 (9), 925-940, 2017 | 162 | 2017 |
| The PROTACtable genome M Schneider, CJ Radoux, A Hercules, D Ochoa, I Dunham, LP Zalmas, ... Nature reviews Drug discovery 20 (10), 789-797, 2021 | 155 | 2021 |
| Behavior of cholesterol and its effect on head group and chain conformations in lipid bilayers: a molecular dynamics study AJ Robinson, WG Richards, PJ Thomas, MM Hann Biophysical journal 68 (1), 164-170, 1995 | 149 | 1995 |
| Chemoinformatics—a new name for an old problem? M Hann, R Green Current Opinion in Chemical Biology 3 (4), 379-383, 1999 | 148 | 1999 |
| Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin PF Chan, V Srikannathasan, J Huang, H Cui, AP Fosberry, M Gu, ... Nature communications 6 (1), 10048, 2015 | 128 | 2015 |
| Implementation of a system for reagent selection and library enumeration, profiling, and design AR Leach, J Bradshaw, DVS Green, MM Hann, JJ Delany Journal of chemical information and computer sciences 39 (6), 1161-1172, 1999 | 109 | 1999 |
| The synthesis and antiviral activity of 4-fluoro-1-β-D-ribofuranosyl-1H-pyrazole-3-carboxamide R Storer, CJ Ashton, AD Baxter, MM Hann, CLP Marr, AM Mason, CL Mo, ... Nucleosides, Nucleotides & Nucleic Acids 18 (2), 203-216, 1999 | 108 | 1999 |
